Erastin: Ferroptosis Inducer Targeting RAS Mutant Tumor Cells

Executive Summary: Erastin (B1524) is a small molecule that induces ferroptosis, a regulated, iron-dependent, and non-apoptotic form of cell death (Yang et al. 2021, DOI). It selectively kills tumor cells with oncogenic mutations in RAS (HRAS, KRAS) or BRAF by disrupting redox homeostasis. Erastin inhibits the cystine/glutamate antiporter system Xc⁻ and modulates the voltage-dependent anion channel (VDAC), causing glutathione depletion and oxidative stress. It is insoluble in water and ethanol but soluble in DMSO at ≥10.92 mg/mL, making it practical for laboratory use. Researchers use Erastin in oxidative stress assays and ferroptosis research, including studies of glioblastoma, pancreatic, and ovarian cancers (APExBIO).

Biological Rationale

Ferroptosis is a distinct, iron-dependent cell death pathway characterized by the accumulation of lethal lipid peroxides. Unlike apoptosis, ferroptosis is caspase-independent and driven by oxidative lipid damage. Tumor cells with mutations in RAS-RAF-MEK signaling pathways, such as those harboring KRAS or BRAF mutations, are particularly susceptible to ferroptosis. This vulnerability arises due to altered redox regulation and increased metabolic demand for antioxidant systems. The cystine/glutamate antiporter system Xc⁻ imports cystine, which is essential for the synthesis of glutathione (GSH), a major cellular antioxidant. Inhibition of system Xc⁻ disrupts GSH synthesis, rendering cells unable to neutralize reactive oxygen species (ROS) and triggering ferroptosis. Targeting this pathway offers a therapeutic strategy for treatment-resistant cancers, including glioblastoma and pancreatic cancer (Yang et al. 2021).

Mechanism of Action of Erastin

Erastin is a small molecule ferroptosis inducer developed for research applications. It operates through two primary mechanisms:

• Inhibition of the cystine/glutamate antiporter (system Xc⁻): Erastin blocks SLC7A11, the key subunit of system Xc⁻, preventing cystine uptake. This leads to glutathione (GSH) depletion and elevated ROS (Yang et al. 2021).
• Modulation of the voltage-dependent anion channel (VDAC): Erastin binds VDAC2/3 on the outer mitochondrial membrane, altering mitochondrial function and promoting oxidative stress (Reference).

These combined actions trigger a cascade culminating in iron-dependent oxidative cell death. Erastin does not activate caspases or typical apoptotic markers, distinguishing it mechanistically from apoptosis inducers (Reference).

Evidence & Benchmarks

• Erastin induces ferroptosis in human glioblastoma cells via GSH depletion and increased ROS; effect is pronounced in p53-SLC7A11-dependent contexts (Yang et al. 2021).
• Selective cytotoxicity observed in tumor cells with oncogenic KRAS or BRAF mutations; minimal toxicity in wild-type cells (APExBIO).
• Typical in vitro treatment: 10 μM for 24 hours in HT-1080 fibrosarcoma cells robustly triggers ferroptosis (Reference).
• Erastin is insoluble in water and ethanol but dissolves in DMSO (≥10.92 mg/mL) with gentle warming; stock solutions are stable at -20°C for several months (APExBIO).
• Ferroptosis induction is iron-dependent and not inhibited by pan-caspase inhibitors, confirming a non-apoptotic mechanism (Reference).

This article updates and extends the mechanistic focus of "Erastin: Precision Ferroptosis Inducer for Cancer Biology..." by emphasizing recent benchmarks and practical workflow integration. It clarifies solution stability and experimental conditions beyond the scenario-driven context of "Erastin (B1524): Scenario-Driven Solutions for Reliable F...".

Applications, Limits & Misconceptions

Erastin is widely used as a research tool in:

• Ferroptosis research: Dissecting iron-dependent, non-apoptotic cell death in cancer and normal cells.
• Cancer biology research: Modeling the vulnerabilities of RAS- or BRAF-mutant tumor cells.
• Oxidative stress assay: Measuring ROS generation and redox homeostasis disruption.
• Therapy resistance studies: Exploring ferroptosis as a strategy to overcome resistance in cancers such as glioblastoma and pancreatic cancer (Yang et al. 2021).

Common Pitfalls or Misconceptions

• Erastin is not an apoptosis inducer: Ferroptosis is caspase-independent; pan-caspase inhibitors do not block its effect.
• Not suitable for water- or ethanol-based assays: Erastin is insoluble in these solvents; only DMSO is appropriate for stock solutions.
• Requires iron for activity: Iron chelators (e.g., deferoxamine) abrogate ferroptosis induction.
• Cell type specificity: Erastin is most effective in cells with RAS or BRAF mutations; wild-type cells may be resistant.
• Instability in solution: Fresh solutions are recommended; prolonged storage at room temperature leads to degradation (APExBIO).

Workflow Integration & Parameters

For optimal results in ferroptosis research and oxidative stress assays:

• Use freshly prepared Erastin solutions (DMSO; ≥10.92 mg/mL) for each experiment.
• Store Erastin powder and stock solutions at -20°C; ship with blue ice.
• Standard in vitro protocol: Treat engineered human tumor or HT-1080 cells at 10 μM for 24 hours.
• Assess cell viability, ROS, and lipid peroxidation to confirm ferroptosis induction.

For detailed, scenario-driven guidance on optimizing assay conditions, see this laboratory Q&A article, which complements the mechanistic overview presented here.

Conclusion & Outlook

Erastin, as provided by APExBIO (B1524), is a validated ferroptosis activator that enables rigorous, reproducible research into iron-dependent, non-apoptotic cell death. Its selectivity for RAS- and BRAF-mutant tumor cells makes it indispensable for studying redox vulnerabilities and ferroptosis-based therapeutic strategies. As the molecular basis of ferroptosis expands, Erastin remains a key tool for dissecting the interplay of lipid metabolism, redox balance, and cancer cell fate (product page). For broader context on mechanistic innovation and translational research, see the synthesis in "Erastin and the Next Frontier of Ferroptosis".